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Substantial statistical research has recently been devoted to the
analysis of large-scale microarray experiments which provide a mea-
sure of the simultaneous expression of thousands of genes in a partic-
ular condition. A typical goal is the comparison of gene expression be-
tween two conditions (e.g., diseased vs. nondiseased) to detect genes
which show differential expression. Classical hypothesis testing pro-
cedures have been applied to this problem and more recent work has
employed sophisticated models that allow for the sharing of informa-
tion across genes. However, many recent gene expression studies have
an experimental design with several conditions that requires an even
more involved hypothesis testing approach. In this paper, we use a
hierarchical Bayesian model to address the situation where there are
many hypotheses that must be simultaneously tested for each gene.
In addition to having many hypotheses within each gene, our analysis
also addresses the more typical multiple comparison issue of testing
many genes simultaneously. We illustrate our approach with an ap-
plication to a study of genes involved in obstructive sleep apnea in
humans.
1. Introduction and motivation. The advent of microarray experiments
for the measure of genome-wide gene expression have had a fundamental
impact on the study of biological mechanisms and phenomena. The simulta-
neous measurements of gene expression across an entire genome have allowed
biologists to infer regulatory networks within genomes [e.g., Segal et al.
(2003)] and investigate the genetic mechanisms underlying disease [e.g.,
Alizadeh et al. (2000)]. The development of models and methodology for
the analysis of gene expression data has also become increasingly promi-
nent within the field of statistics. Sophisticated procedures have been imple-
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mented for the processing and visualization of expression data [e.g.,
Dudoit, Gentleman and Quackenbush (2003), Irizarry et al. (2006)] as well
as the clustering of expression data [e.g., Medvedovic and Sivaganesan (2002),
Ma et al. (2006)]. Hypothesis testing of expression data has also been an area
of active research, with considerable focus given to proper techniques for in-
ference in the context of large numbers of simultaneous tests across many
genes [e.g., Storey and Tibshirani (2003), Newton et al. (2004)].
In this paper we consider a special case of simultaneous testing not just
across many genes but also across many hypotheses within each gene. Our
consideration of this case is motivated by our analysis of a large study of
treatment for obstructive sleep apnea (OSA) where we are comparing many
genes across several states. Obstructive sleep apnea is a common sleep disor-
der involving frequent and disruptive pauses in breathing during sleep [Pack
(2006)]. A large study of sleep apnea involving 13 individuals was under-
taken in 2005 by Landspitali University Hospital in Iceland. The primary
goal of this study was the elucidation of genes whose expression pattern
was mediated by an obstructive sleep apnea treatment: continuous positive
airway pressure (CPAP). The experimental design of their study consists
of the 13 individuals with blood samples taken at the following four time
points:
1. Pre-treatment, Before Sleep,
2. Pre-treatment, After Sleep (10 hours following time point 1),
3. Post-treatment, Before Sleep (12 weeks following time point 2),
4. Post-treatment, After Sleep (10 hours following time point 3).
In this paper we will use the terms state and time point interchangeably.
From the blood samples taken at each time point, cellular mRNA expression
was measured using Affymetrix microarray technology for approximately
22,000 genes. These expression levels are used as a measure of the activity
of each gene: genes that show high expression levels in a state are considered
to be activated, genes that show low expression levels in a state are consid-
ered to be repressed. The overall goal of our analysis will be the identification
of any genes that show differential expression within some subset of these
four time points. We have specific interest in differential expression between
particular subsets of the time points, such as genes that show differences
between the before and after states of sleep, or genes that show differences
between the before and after states of the treatment. Genes which can be
found to have their mRNA expression that is mediated by the CPAP treat-
ment are valuable candidates for follow-up studies into refined treatments
for sleep apnea.
We will take a hypothesis testing approach to the determination of differ-
ential expression between these states. Linear models have been used ex-
tensively for establishing differential gene expression, such as the limma
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package for R [Smyth (2004)]. We prefer the use of a Bayesian hierarchi-
cal model to allow for gene-specific differences in expression while sharing
information across genes for the estimation of several global noise param-
eters. Bayesian models have been recently used for hypothesis testing be-
tween two states [Newton et al. (2004)] and we will use a similar modeling
approach in our current work. However, our present application has several
complications that require new methodological development. The applica-
tion in Newton et al. (2004) consisted of only two states, which greatly sim-
plifies the testing situation since there are only three distinct hypotheses
(µ1 = µ2, µ1 > µ2, µ1 < µ2) that could describe the expression of any par-
ticular gene. However, our application consists of four states, which greatly
expands the number of alternative hypotheses that might underly the ob-
served expression values for each gene. Kendziorski et al. (2003) extend the
approach of Newton et al. (2004) to greater than two states, but under the
restriction that only two-sided alternatives are considered (e.g., µ1 = µ2 = µ3
vs. µ1 = µ2 6= µ3). This is a restrictive assumption in our context since
we desire the separate identification of activated and repressed genes be-
tween subsets of states. We prefer to take a fully flexible approach that
allows for all possible one-sided alternatives which leads to a substantially
larger space of many possible hypotheses for each gene, and we present our
Bayesian hierarchical model for the testing of many hypotheses in Section 2.
Yuan and Kendziorski (2006) extend the approach of Newton et al. (2004)
to also allow clustering of genes in addition to establishing differential ex-
pression. However, Yuan and Kendziorski (2006) take an empirical Bayes
approach to model estimation instead of modeling the entire posterior dis-
tribution of all unknown parameters. Thus, these previous approaches have
favored inference based on a posterior mode found via the EM algorithm
[Dempster, Laird and Rubin (1977)], whereas we prefer a full exploration
of the posterior space using Markov chain Monte Carlo techniques such as
Gibbs Sampling [Geman and Geman (1984)].
However, we also must confront a more traditional multiple comparison
issue: we are not only testing many hypotheses per gene, but also testing
across many genes in our full evaluation of the effects between pre- and
post-treatment sleep apnea. In Section 2.2 we outline our approach to con-
trolling the false positive rate across genes by using the posterior probabili-
ties across hypotheses estimated within each gene. Combined together, these
procedures are a principled approach to the increasingly common hypothesis
testing context where there are many hypotheses × many genes. In Section 3
our model is applied to the gene expression data from our motivating study
of sleep apnea, and in Section 4 we perform an extensive study of the sen-
sitivity of our inference to several model choices and compare our results to
two alternative models available as R packages: limma and EBarrays. We
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examine several individuals in detail as potential outlying values and evalu-
ate their influence on our gene-specific inferences, as well as examining the
possibility of the correlation between individuals in the study. We conclude
with a brief discussion in Section 5.
2. Model and implementation.
2.1. Gamma–Inv-Gamma hierarchical model. Our observed data isXgij =
expression level of gene g (g = 1, . . . ,G) in state i (i= 1, . . . ,4) for individual
j (j = 1, . . . ,N ). For our Iceland study, we have G= 22,283 genes measured
across N = 13 individuals. We model these gene expression values as Gamma
observations from an underlying gene- and state-specific mean:
Xgij ∼Gamma
(
αi,
αi
µgi
)
, i.e.,E(Xgij) = µgi.(1)
As mentioned by Newton et al. (2004) and Yuan and Kendziorski (2006),
the Gamma distribution is an attractive model for expression data since
many popular processing and normalization procedures lead to expression
data with approximately constant coefficient of variation. The Gammamodel
has constant coefficient of variation for the genes in each state, but the co-
efficient of variation is allowed to vary across states. Newton et al. (2001)
also discuss the Gamma distribution as a model for gene expression data,
though that discussion focussed on two-channel cDNA microarrays instead
of the Affymetrix microarray technology employed in our study.
The second level of our model treats the latent means µg = (µg1, . . . , µg4)
for a particular gene g in each of the four states as random variables that
each follow an inverse-Gamma distribution,
µgi ∼ Inv-Gamma(α0, α0 · µ0),(2)
but with additional constraints on the vector µg = (µg1, . . . , µg4) dictated
by a latent variable Zg. Each constraint Zg represents a different hypothe-
ses (e.g., µg1 = µg2 = µg3 < µg4) on the underlying means for gene g. We
have adopted several elements of the model and notation of Newton et al.
(2004), but our model is more complex in the sense we are modeling four
states simultaneously, which substantially increases the number of possible
hypotheses for our underlying means. For four states, there are 75 possible
orderings of our µ vector when including all possible subsets of equalities:
Zg = 0 =⇒ µg1 = µg2 = µg3 = µg4,
Zg = 1 =⇒ µg1 = µg2 = µg3 < µg4,
Zg = 2 =⇒ µg1 = µg2 = µg3 > µg4,
...
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A full list of the 75 different hypotheses are given in our supplementary
materials [Jensen et al. (2009)]. We use additional notation to keep track of
the different orderings Zg in order to address the extra complexity of our
problem and allow for easier generalization to applications with more than
four states. Let M(Zg) be the number of equality groups in the ordering,
and let C(Zg,m) be the set of time-points or states contained in the mth
equality group of that ordering. We then rank the equality groups in increas-
ing order, so that C(Zg) = [C(Zg,1), . . . ,C(Zg,M(Zg))], where the members
of C(Zg,1) have lower means than members of C(Zg,2) which have lower
means than members of C(Zg,3), etc. Consider a few examples:
Zg = 0 : µ1 = µ2 = µ3 = µ4
=⇒ M(Zg) = 1, C(Zg) = [(1,2,3,4)],
Zg = 1 : µ1 = µ2 = µ3 < µ4
=⇒ M(Zg) = 2, C(Zg) = [(1,2,3), (4)],
Zg = 2 : µ1 = µ2 = µ3 > µ4
=⇒ M(Zg) = 2, C(Zg) = [(4), (1,2,3)],
...
Finally, we have additional parameters that specify the probabilities for each
mixture component: P(Zg = k) = φk for k = 0, . . . ,74. The complete-data
likelihood of our model combines our unknown parameters Θ = (α, µ0,φ)
and observed data X with our latent variables µ and Z as follows:
p(X,µ,Z|Θ) =
G∏
g=1
[
4∏
i=1
p(Xgi|µgi,Θ)
]
· p(µg|Zg,Θ) · p(Zg|Θ).(3)
We use noninformative prior distributions for each unknown parameter in
Θ= (α, µ0,φ):
1. φ∼Dirichlet(ω) where each ωk is small (ωk = 0.001 for this study).
2. αi ∼Uniform(0,C) where C is large (C = 10,000 for this study).
3. µ0 ∼Uniform(0,C) where C is large (C =10,000 for this study).
Our posterior inference was not sensitive to other choices of C and ωk. We
can reduce the complexity of our model estimation by integrating over the
latent gene- and state-specific means µ:
p(X,Z|Θ) =
∫
p(X,µ,Z|Θ)dµ
=
G∏
g=1
p(Zg|Θ)
∫ [ 4∏
i=1
p(Xgi|µgi,Θ)
]
· p(µg|Zg,Θ)dµg,
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which results in the following collapsed likelihood distribution:
p(X,Z|Θ) =
G∏
g=1
φZg ·D(Zg) ·
(α0µ0)
α0·M(Zg)
[Γ(α0)]M(Zg)
(4)
×
4∏
i=1
αNαii
[Γ(αi)]N
N∏
j=1
Xαi−1gij
M(Zg)∏
m=1
Γ(A(g,m))
(B(g,m))A(g,m)
,
where A(g,m) = α0+N ·
∑
cαc and B(g,m) = α0µ0+
∑
c αc
∑
jXgcj with c ∈
C(Zg,m). The factor D(Zg) is a constant related to the posterior probability
of the ordering itself, which is rather complicated and discussed in detail
in our supplementary materials [Jensen et al. (2009)]. Finally, we combine
this collapsed likelihood together with our prior distributions to give us the
full posterior distribution, p(Θ,Z|X) ∝ p(X,Z|Θ) · p(Θ), of our unknown
parameters Θ and latent variables Z.
An alternative modeling approach for the multiple group problem is pro-
vided by Gottardo et al. (2006). Their model is based on the t-distribution
for the observed expression measures with mixtures of normal prior distri-
butions for the unobserved means. However, their approach lacks the con-
jugacy of our model, and thus the unknown means µ cannot be integrated
out of their model. Subsequently, the Gottardo et al. (2006) implementa-
tion is more complicated since they must estimate all the unknown means
µ, whereas we can focus our estimation on a much smaller set of parame-
ters Θ. We implement our collapsed model using a relatively simple Gibbs
sampling [Geman and Geman (1984)] algorithm that approximates the full
posterior distribution of our unknown parameters (Θ,Z) by sampling it-
eratively from the conditional distribution of each set of parameters given
the current values of the other parameters. Details of our Gibbs sampling
algorithm are given in the supplementary materials [Jensen et al. (2009)].
2.2. Inference for gene-specific hypotheses Zg and multiple comparison
issues. The primary goal of our investigation is to infer the correct hy-
pothesis Zg for each gene, with extra focus on genes that are inferred to
be nonnull (Zg 6= 0). Our Gibbs sampling algorithm provides an estimate
of the posterior distribution for each latent variable Zg, but we still need
to make a decision about which hypothesis we infer to be correct for each
gene. There are several different inferential decisions we can make based on
the posterior distribution of each Zg. The first alternative is to assign each
gene to their modal hypothesis,
h˜g = arg max
h=0,...,74
P(Zg = h|X).(5)
As discussed in Bickel and Doksum [(2007), page 165] using the hypothesis
with the largest posterior probability is an optimal strategy under a 0–1 loss
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function. However, using the modal hypothesis for each gene ignores poten-
tially important information about the confidence of our inference in each
gene-specific decision. Given two genes (A and B) with modal hypothesis h′,
we might wish to draw a distinction between gene A with P(ZA = h
′|X) = 0.9
and gene B with P(ZB = h
′|X) = 0.4. One popular inferential technique is
to only declare genes to have a particular hypothesis h′ if their posterior
probability P(Zg = h
′|X) exceeds a pre-defined threshold k. In biological
applications where tests are being performed across many genes simultane-
ously, this threshold k is chosen so that the false discovery rate (FDR) is
controlled at a desired level (say, 0.05). Our Bayesian framework allows us
to use our gene-specific posterior probabilities P(Zg|X) to directly estimate
the false discovery rate for any threshold k. Newton et al. (2004) suggest
the following formula for the estimated false discovery rate for a threshold
of k:
FDR(k) =
∑
g P(Zg = 0|X)× I[P(Zg 6= 0|X)≥ k]∑
g I[P(Zg 6= 0|X)≥ k]
.(6)
The term P(Zg = 0) is the probability of an error when declaring gene g
to have a nonnull hypothesis [P(Zg 6= 0|X)≥ k]. Equation (6) was valid for
the Newton et al. (2004) study since they were only concerned with FDR
control for ordered comparisons between two states. However, in our current
methodology, we not only have to control our inference across many genes,
but also across many different ordered hypotheses within each gene. In this
more complicated situation, equation (6) actually underestimates the error
rate, since it only measures null vs. nonnull errors without accounting for an
additional potential error: a gene correctly declared to be nonnull, but the
incorrect nonnull hypothesis is inferred. In our many hypotheses × many
genes situation, we suggest the following estimated false discovery rate for
a threshold of k:
FDR(k) =
∑
g P(Zg 6= hg|X)× I[P(Zg = hg|X)≥ k]∑
g I[P(Zg = hg|X)≥ k]
,(7)
where hg = 1, . . . ,74 is the nonnull hypotheses that is chosen for gene g. A
nonnull hypothesis hg is only chosen for gene g if it is the modal hypothesis
and P(Zg = hg|X)≥ k. In these cases, P(Zg 6= hg|X) is the probability of an
error when declaring gene g to have a specific nonnull hypothesis hg. Given a
complete set of estimated posterior probabilities P(Zg|X), equation (7) can
be calculated along a fine grid of potential thresholds k ∈ (0,1), and then a
particular k⋆ is chosen to control the false discovery rate at the desired level
(e.g., 0.05).
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3. Results. The raw Affymetrix data was processed using the GC-RMA
procedure presented in Wu et al. (2004). This preliminary analysis gives
us a dataset consisting of expression levels for 22,283 genes across the 4
states in 13 individuals. We implemented our model on this dataset using
the Gibbs sampler outlined in our supplementary materials [Jensen et al.
(2009)]. Multiple chains of the Gibbs sampler were run for 20,000 iterations.
A thorough examination of the parameter values from these chains suggested
that the chains had converged to the true posterior distribution after the
first 5000 iterations. These initial 5000 iterations were discarded as burn-in,
and our inference is based on the remaining iterations. We first examine our
model parameters Θ in Section 3.1 and then focus on our primary goal:
gene-specific inference for our Z indicators in Section 3.2.
3.1. Inference for model parameters Θ. We examine our model param-
eters Θ by first considering the global parameters (α, µ0) which are shared
across all genes. In Figure 1 we present the posterior distributions of the
global parameters (α1, α2, α3, α4) from our observed data level (1) as well as
the global parameters (α0, µ0) from our latent variable level (2). We see in
Figure 1 that there is variability in each parameter which is only captured
by our estimation of the full posterior distribution, compared to previous ap-
proaches [Newton et al. (2004), Yuan and Kendziorski (2006)] that focussed
on point estimates of each parameter. Another interesting result from Figure
1 is that the distributions of the shape parameters (α1, α2, α3, α4) are each
centered at different values, suggesting that there are global differences in
the gene expression measures between the four states of the experiment.
The other global parameters φ= (φ0, φ1, . . . , φ74) represent the marginal
probabilities of each hypothesis across the 22,283 genes in our dataset. In
Figure 2 we present the posterior means of the marginal probability φk for
each hypothesis k, as estimated from our Gibbs sampling output. All 75
hypotheses are represented in the left barplot in Figure 2, but only the 74
nonnull hypotheses are present in the right barplot. The most striking fea-
ture of Figure 2 is the sparsity of the probabilities over the set of possible
hypotheses. The null hypotheses (µ1 = µ2 = µ3 = µ4) dominates with a pos-
terior mean φ0 = 0.735. This is an expected result, since the majority of
genes are involved in cellular processes that are not circadian or affected by
sleep vs. wakeful state. In order to illuminate other popular hypotheses, we
removed the null hypotheses from the comparison in the bottom plot of Fig-
ure 2. The other prominent hypotheses are hypothesis 10 (µ1 = µ3 < µ2 = µ4)
with φ10 = 0.118 and hypothesis 13 (µ1 = µ3 > µ2 = µ4) with φ13 = 0.078.
These two hypotheses represent genes that show change between morning
and evening but do not seem to show change between time point 2 and
time point 3. These genes can be either circadian, affected by sleep or by
other changes that occur between the evening and morning measurements.
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Fig. 1. The first set of boxplots are the posterior distributions for the global parameters
(α1, α2, α3, α4) from our observed data level. The second set of boxplots are the posterior
distributions of the global parameters (α0, µ0) from our latent variable level.
We will refer to these genes as circadian in our subsequent analysis. The
remaining hypotheses represent genes that could be affected by treatment
(i.e., either µ1 6= µ3 or µ2 6= µ4). As seen in Figure 2, these other hypotheses
have quite low marginal posterior probabilities, with the highest probabil-
ity among them being hypothesis 32 (µ1 = µ3 < µ4 < µ2) with φ32 = 0.001.
However, it is important to emphasize that although the marginal posterior
probabilities of these hypotheses are quite small, there are still many genes
from our pool of 22,283 genes that can be inferred into these hypotheses, as
we see in Section 3.2 below.
3.2. Inferred hypotheses for each gene. The primary goal of our analysis
is to infer the correct hypothesis for each gene in our dataset, which is repre-
sented in our model by the latent indicator variable Zg for g = 1, . . . ,22,283.
Naturally, we are especially interested in inferring the correct hypothesis for
genes that do not seem to be in the null category Zg = 0. Our Gibbs sam-
pling implementation gives us an estimate of the P(Zg = h|X) for each of
the 75 possible hypotheses for gene g. As described in Section 2.2, we infer a
particular nonnull hypotheses h′ to be correct for gene g if P(Zg = h
′|X)> k
where the threshold k is chosen to control the false discovery rate given in
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Fig. 2. Plot (a) is a barplot of the posterior mean of φk for the ten hypotheses with the
largest values of φk. Plot (b) is a barplot of the posterior mean of φk for the ten hypotheses
(excluding the null hypothesis) with the largest values of φk.
(7). Genes with P(Zg = h
′|X) that do not achieve this threshold for any
nonnull hypothesis are inferred to be in the null category. It is worth noting
again that this procedure is designed to control the false discovery rate for
not only the multiple comparisons across many genes but also the multi-
ple comparisons across many hypotheses within each gene. For our dataset
of 22,283 genes, the threshold k = 0.645 controls the FDR below a level of
0.05. Using this threshold gives us 4083 genes (18%) that are inferred to
have nonnull hypotheses. The number of genes that were inferred to have
each nonnull hypotheses Zg = h (h= 1, . . . ,74) are given in Table 1.
From Table 1, we see that many nonnull hypotheses are inferred for at
least one gene in our dataset, despite the relatively low marginal probability
of most of these hypotheses (Section 3.1). Hypotheses 10 and 13, which are
circadian genes, are by far the most popular nonnull hypotheses (98% of
nonnull genes). However, there are several groups of genes that do not have
a circadian pattern, with the most prominent being hypotheses 25 (µ4 <
µ2 < µ1 = µ3) and 32 (µ2 > µ4 > µ1 = µ3). Genes with these two inferred
BAYESIAN HYPOTHESIS TESTING 11
Table 1
Number of inferred genes and marginal probabilities φg for each inferred hypothesis
Zg Hypothesis φg Number of inferred genes
10 µ1 = µ3 <µ2 = µ4 0.11791 2433
13 µ2 = µ4 <µ1 = µ3 0.07822 1580
25 µ4 < µ2 <µ1 = µ3 0.00099 9
32 µ2 > µ4 >µ1 = µ3 0.00111 7
3 µ3 < µ1 = µ2 = µ4 0.00095 5
33 µ3 > µ1 >µ2 = µ4 0.00095 5
4 µ4 < µ1 = µ2 = µ3 0.00095 4
21 µ3 < µ1 <µ2 = µ4 0.00096 4
6 µ2 > µ1 = µ3 = µ4 0.00099 3
28 µ1 > µ3 >µ2 = µ4 0.00099 3
2 µ2 < µ1 = µ4 = µ3 0.00095 2
5 µ1 > µ2 = µ3 = µ4 0.00095 2
9 µ1 = µ2 <µ3 = µ4 0.00095 2
20 µ2 < µ4 <µ1 = µ3 0.00095 2
37 µ4 > µ2 >µ1 = µ3 0.00095 2
43 µ2 < µ1 = µ4 < µ3 0.00095 2
48 µ4 < µ1 = µ2 < µ3 0.00095 2
61 µ2 < µ4 <µ1 < µ3 0.00095 2
64 µ3 < µ1 <µ4 < µ2 0.00095 2
71 µ4 < µ2 <µ1 < µ3 0.00095 2
7 µ3 > µ1 = µ4 = µ2 0.00094 1
8 µ4 > µ1 = µ2 = µ3 0.00094 1
14 µ3 = µ4 <µ2 = µ1 0.00094 1
16 µ1 < µ3 <µ2 = µ4 0.00094 1
22 µ3 < µ2 <µ1 = µ4 0.00094 1
39 µ1 < µ2 = µ3 < µ4 0.00094 1
42 µ2 < µ1 = µ3 < µ4 0.00094 1
44 µ2 < µ3 = µ4 < µ1 0.00094 1
51 µ1 < µ2 <µ3 < µ4 0.00094 1
72 µ4 < µ2 <µ3 < µ1 0.00094 1
hypotheses show identical pre-sleep expression levels both before and after
treatment (µ1 = µ3), but different post-sleep expression patterns between
the before and after treatment time points (µ2 6= µ4). The next two most
popular hypotheses, 3 (µ3 <µ1 = µ2 = µ4) and 33 (µ3 >µ1 >µ2 = µ4), show
the opposite trend with the same expression levels post-sleep before and after
treatment (µ2 = µ4), but different activity in the pre-sleep points before and
after treatment (µ3 6= µ1). In both situations, it is possible that the applied
treatment is affecting some cellular process involving these genes. These
genes are candidates for follow-up analyses into the genetic basis of sleep
behavior, as well as more refined potential treatments of sleep apnea.
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Table 2
Description of collapsed hypotheses groupings and results from our model compared to the
EBarrays software discussed in Section 4.1
Our Model EBarrays
Description Marginal# of inferredMarginal# of inferred
Label(contained hypotheses) probs φ genes probs φ genes
C0 Null: µ1 = µ2 = µ3 = µ4 0.735 18,013 0.752 17,374
(0)
C1 Circadian: µ1 = µ3 6= µ2 = µ4 0.196 4102 0.228 4636
(10, 13)
C2 Treatment-affected A: µ1 6= µ2 but 0.009 18 0.001 18
µ3 = µ4 (1, 2, 5, 6, 15, 18, 27, 30, 41, 44)
C3 Treatment-affected B: µ1 = µ2 but 0.009 29 0.002 13
µ3 6= µ4 (3, 4, 7, 8, 23, 26, 35, 38, 45, 48)
3.3. Collapsing hypotheses groups. We can further refine our search for
treatment-mediated genes by collapsing our 74 possible nonnull hypotheses
into a smaller set of hypothesis groups of particular biological interest. As
an example, we can combine hypothesis 10 and hypothesis 13 into a single
hypothesis group C1 of genes that are circadian (µ1 = µ3 6= µ2 = µ4). Sim-
ilarly, we can combine the ten different hypotheses for which µ1 6= µ2 but
µ3 = µ4 into a single hypothesis group C2 of genes that may be affected
by the treatment. Also of interest is the opposite group C3 of genes that
may be affected by the treatment (µ1 = µ2 but µ3 6= µ4). These hypothesis
groupings are listed in Table 2. For now, we focus on the results from our
model which are given in the third and fourth column of Table 2.
For any particular gene, the posterior probability of belonging to a par-
ticular hypothesis group (e.g., C1) can be calculated directly by summing
the estimated probabilities P(Zg = h|X) over all hypotheses contained in
that group. Our procedure for choosing an FDR-calibrated threshold (Sec-
tion 2.2) can then be performed on this collapsed set of hypothesis groups
instead of the full set of hypotheses. For this collapsed set of hypothesis
groups, a threshold k′ = 0.595 controls the FDR below a level of 0.05, which
is a slightly more liberal threshold than k = 0.645 used in our un-collapsed
analysis in Section 3.2. Using this threshold, we infer 4270 genes to have
nonnull hypotheses, compared to the 4083 genes inferred to be nonnull in
Section 3.2. The number of genes inferred into each collapsed hypotheses
grouping is also given in Table 2. We see that the inferred nonnull genes are
still dominated by circadian genes, but there are quite a few genes in the
C2 and C3 groups (18 and 29 resp.) that seem to be affected by treatment.
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4. Model comparison and sensitivity. We have presented a sophisticated
hierarchical model to address the many hypotheses × many genes situation
presented by the current sleep apnea study. In this section we compare our
analysis to results from a related method by Yuan and Kendziorski (2006),
and discuss differences and limitations. In addition, the complexity of our
approach requires us to verify the validity of several model assumptions in
detail. We explore the possibility that one or two suspicious patients have a
substantial effect on our inference in Section 4.3. In Section 4.4 we explore
the potential consequences of one simplifying assumption of our model, that
our gene expression measurements within each timepoint are treated as in-
dependent replications. Finally, in Section 4.5 we evaluate the sensitivity of
our model by examining the empirical effect sizes for the inferred genes for
several different hypotheses.
4.1. Comparison with the limma and EBarrays procedures. As discussed
in our introduction, there have also been several recent applications of
Bayesian hypothesis testing to gene expression data [Kendziorski et al. (2003),
Newton et al. (2004), Yuan and Kendziorski (2006)]. The EBarrays R pack-
age (version 2.2.0) implements a version of these general approaches that
allows for testing of multiple hypotheses in a similar fashion to our proposed
methodology. However, the EBarrays procedure differs from our model in
several important ways. First, parameter estimation in EBarrays is per-
formed using an EM algorithm [Dempster, Laird and Rubin (1977)] which
focuses on point estimation instead of our favored approach of estimating the
full posterior distribution of each parameter. Second, a single shape parame-
ter α is used for all states in the observed data level, which in our notation is
equivalent to assuming α1 = α2 = α3 = α4 = α. The estimated value of their
single parameter is αˆ= 21.3, which is within the range of our αi values. How-
ever, as we see in Figure 1, our analysis finds substantial differences in the
posterior distributions of our separate αi parameters that is not modeled in
EBarrays. On a more technical note, although EBarrays is capable of han-
dling ordered alternative hypotheses, the full set of 75 hypotheses ordered
hypotheses used by our analyses could not be fit by EBarrays (errors were
produced within the EBarrays version 2.2.0 optimization routine). Instead,
we used EBarrays to fit the full set of twelve unordered hypotheses. We
focus our attention on the EBarrays results for the unordered hypotheses
that correspond to our collapsed hypotheses groupings examined in Section
3.3.
Similar to our method, EBarrays produces parameter point estimates as
well as posterior probabilities for each gene × hypothesis combination. We
use the same FDR control procedure described in Section 2.2 to infer genes
into each hypothesis. In Table 2 we compare EBarrays to our analysis in
terms of the marginal probabilities φ and number of inferred genes for each
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hypothesis grouping. Assuringly, there are some strong similarities between
our analysis and the results produced by EBarrays, such as the correspon-
dence between the analyses on the marginal probability of the null hypothe-
ses φ0. The most striking difference between the results is that many more
genes are inferred into the circadian category (C1) by EBarrays, whereas
we see slightly more genes inferred into the treatment category C3 with our
method. This small difference could be due to a decreased resolution toward
rare hypotheses caused by the EBarrays assumption of a single shape pa-
rameter α shared across all four states. We also compared our results to a
much simpler analysis based on a linear model as implemented by the limma
R package. In the standard limma approach, significant genes are identified
by examining the p-values associated with differences in gene-specific co-
efficients between different states (after a Bonferroni–Holm correction for
multiple testing). We tested for both significant circadian genes (C1 cate-
gory), as well as genes that showed significant differences between states but
not a circadian pattern, such as the C2 and C3 treatment categories out-
lined in Section 3.3. When using limma to examine the entire set of genes for
any significant differences from the null hypothesis, we found 79.9% of genes
were categorized in the null category, which is larger than the null propor-
tion found by either our method or EBarrays. We also found that among the
nonnull genes found by limma, only a very small number (twelve genes) were
categorized as something other than circadian, which is a much smaller than
the number of nonnull and noncircadian genes found by our method (given
in Table 1). It appears that the simple analysis by limma does not have
the resolution necessary to detect genes that show noncircadian differential
expression.
4.2. Evaluation of model characteristics. A central assumption of our
approach is the use of a Gamma distribution to model our gene expression
observations in each state. Newton et al. (2004) discuss diagnostics to ap-
praise the reasonableness of this Gamma assumption by examining the data
for constant coefficient of variation. If the assumption of constant coefficient
of variation is tenable, then genes ranked by their coefficient of variation
should not share any relationship with genes ranked by either their mean or
standard deviation. In Figure 3 we plot genes ranked by coefficient of vari-
ation against genes ranked by means, as well as genes ranked by standard
deviations. We see from Figure 3 that there is no substantial relationship
between the coefficient of variation and the mean or standard deviation,
though there is some nonuniformity in the extremes. However, it is worth
noting that only a subset of the 22,283 genes in our dataset is depicted in
Figure 3. There is a substantial set of remaining genes that have very low
expression values, and correspondingly low variance of those expression val-
ues. The low variance of these additional genes would skew the appearance
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of the diagnostic plots presented in Figure 3 if they were included. However,
these additional genes are not of primary interest since their low expression
values put them into the null hypotheses category. The main worry is that
the presence of these low expression genes will affect the ability of our model
to detect nonnull hypotheses. To investigate this possibility, we designed a
small simulation study where realistic synthetic data was generated that
contained both null and nonnull genes, as well as many null genes that have
low-variance low-expression values. In these simulated experiments, our ap-
proach was still able to detect the true nonnull genes despite the presence
of a substantial number of low-variance, low-expression null genes.
In addition to using simulated data to investigate our gamma assump-
tion, we also designed an extensive simulation study to evaluate the general
performance of our approach in carefully controlled situations. Specifically,
we set global parameter values of α0 = 5, µ= 9 and α1 = α2 = α3 = α4 = 25
which approximate the characteristics of our sleep apnea dataset (as seen in
Figure 1). With these realistic global parameter values, we then consider two
Fig. 3. (a) Rank of genes by coefficient of variation against rank of genes by mean. (b)
Rank of genes by coefficient of variation against rank of genes by standard deviation.
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data situations: datasets containing 100 genes each versus datasets contain-
ing 200 genes each. Each of these datasets contained a mixture of approx-
imately 75% null genes and 25% nonnull genes. Note that these simulated
datasets are much smaller than our sleep apnea study, which gives us the
chance to examine the operating characteristics of our model in limited data
situations. We implemented our model on one hundred datasets generated
from each of these two data situations, and the results are shown in Table 3.
We see from the results in Table 3 that our model achieves accurate
estimates for the global parameters (α1, α2, α3, α4) even in these limited
data situations. More problematic is the global parameter α0, which only
has 82% coverage in the smaller (N = 100) datasets. The coverage improves
for α0 in the larger (N = 200) datasets, though even larger datasets seem
to be needed to achieve proper coverage for this parameter. Also, even in
these small datasets, our model classifies close to the correct number of
nonnull genes, and the small amount of error is in the conservative direction
of a decreased number of nonnull classifications. Overall, these simulation
results are encouraging in terms of our model’s ability to achieve reasonable
inference even in limited data situations, which bodes well for our sleep
apnea application where the available data is much more extensive.
4.3. Effect of outlier patients. Two of the thirteen patients in our study
were flagged by researchers at the University of Iceland as having phenotypic
differences from the other eleven patients. These two patients (labeled here
as patient X and patient Y) are potential outliers that could have a dramatic
effect on our model inference. To address this possibility, we also fit our
hierarchical Bayesian model on datasets that had either (or both) of these
Table 3
Parameter estimates for synthetic data generated under two conditions: N = 100 genes
vs. N = 200 genes. For each global parameter, we give the mean across simulated
datasets as well as the coverage of the 95% posterior intervals. We also give the mean ±
standard deviation (across datasets) for the proportion of inferred nonnull genes
Global
parameter
True
value
N= 100 genes N= 200 genes
Mean 95% coverage Mean 95% coverage
α0 5 6.68 82 5.25 86
µ0 9 9.04 96 9.01 98
α1 25 25.01 97 25.03 98
α2 25 24.93 96 25.14 97
α3 25 25.20 100 24.98 98
α4 25 24.99 95 25.07 97
Proportion of 0.25 0.231± 0.041 0.233± 0.033
nonnull genes
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Fig. 4. Posterior mean of φk for the five hypotheses with the largest values of φk from
all four analyses (A–D).
patients removed. These alternative analyses are listed in Table 4 along with
our original model fit from Section 3 labeled as “Analysis A.”
Similar to our analysis of the original dataset from Section 3, we first
examine the estimated marginal posterior probabilities φ from each analy-
sis. The estimated posterior means of the marginal probability φk for each
hypothesis k for all four analyses (A–D) are given in Figure 4. We can
see that the four analyses share the same characteristics: the estimated φ
are sparsely distributed, with the vast majority of mass concentrated at
hypotheses 0 (null), 10 and 13. However, as seen in Section 3.2, there is
additional information at the level of the inferred hypotheses for individual
genes, and so we also compared our four analyses in terms of differences in
the inferred gene-specific hypotheses.
For each alternative analysis (B, C and D), we calculated the number
of discrepancies with analysis A, which we define as any genes that have a
different inferred hypothesis compared to the original analysis. The number
of discrepancies for each alternative analysis are given in Table 4, along with
the number of genes with nonnull inferred hypotheses for each analysis. The
first observation is the relatively small number of discrepancies between the
methods, compared to the total number of genes in our dataset. In fact,
20,658 out of 22,283 genes (93%) showed no discrepancy across any of the
three alternative analyses. Looking at pairwise differences, removing patient
X reduces the number of genes with inferred nonnull hypotheses (from 4083
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Fig. 5. Clustering tree of patients based on gene expression correlation.
down to 3437) relative to our original analysis, whereas removing patient Y
increases the number of genes with inferred nonnull hypotheses (from 4083
up to 4521). The removal of both patients seems to balance these two effects,
which leads to the least number of discrepancies (596) when compared to
our original analysis. These results seem to suggest that our original analysis
with all patients included achieves a compromise between the more extreme
results from the alternative analyses with either patient X or patient Y
excluded.
4.4. Applying the model to clusters of individuals. In our sleep apnea
study, expression levels are measured for the same 13 individuals in each
state, and it is likely that there will be correlation between individuals that
could influence our inference. We will examine the consequences of this pos-
sibility by first grouping individuals that have correlated gene expression
Table 4
Discrepancies between different analyses
Analysis Analysis Discrepancies Number of
label description with analysis A nonnull genes
A Original dataset with all 13 patients 0 4083
B Patient X excluded from dataset 774 3437
C Patient Y excluded from dataset 887 4521
D Both patient X and patient Y 596 3642
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patterns across states. We calculated the correlation of gene expression pat-
terns between each pair of individuals and used these correlations as a dis-
tance metric for clustering (distance = 1− correlation). We then constructed
a hierarchical clustering tree based on this distance metric, shown in Fig-
ure 5, to group our individuals into two clusters. From Figure 5, it is clear
that the most reasonable partitioning of our individuals into two groups in-
volves the three patients 3, 6 and 10 in one cluster, and the remaining 10
patients in the other cluster. We then fit our full Bayesian hypothesis testing
model separately within each cluster, while allowing for different fitted model
parameters and inferred hypotheses for each gene within each cluster. Fi-
nally, we examined the inferred hypotheses in each cluster for discrepancies
between clusters as well as discrepances with our original analysis. Inter-
estingly, we found no discrepancies between the two clusters of individuals:
every gene had the same inferred hypothesis in the cluster 1 and cluster 2
datasets. However, we did find discrepancies between the clustered analysis
and our original unclustered analysis: 2365 out of 22,285 genes (11%) had
a different inferred hypothesis. Almost all of these discrepancies (2363 out
of 2365) are genes that were inferred to be nonnull in our original unclus-
tered analysis but now are inferred to be in the null group in our clustered
analysis. In fact, the only nonnull hypotheses that contained genes in our
clustered analysis were hypotheses 10 and 13 (circadian genes not affected
by the sleep apnea treatment). One explanation for these results is that split-
ting the dataset into two clusters leads to a reduced sample size within each
cluster and thus makes nonnull hypotheses more difficult to infer from the
data. A possible extension of our approach would be to allow the clustering
of individuals to vary instead of only examining the particular clusters we
used above. However, we believe that we are taking a conservative approach
since the clusters used in our analysis were chosen in order to create the
most dramatic difference between clusters.
4.5. Empirical evaluation of effect sizes. One concern when implement-
ing a model with a large space of hypotheses on data with a relatively small
number of individuals (n= 13) is that inference will not be sensitive enough
to detect genes with small effect sizes. We explore this issue by examin-
ing the observed effect sizes for genes that were inferred to have significant
differences (nonnull hypotheses) by our analysis. Specifically, we examine
particular hypotheses of two different types:
1. Hypothesis 10 (µ1 = µ3 < µ2 = µ4) which is one of the popular circadian
hypotheses. Hypothesis 10 was inferred for 2433 genes by our analysis.
2. Hypothesis 3 (µ3 < µ1 = µ2 = µ4) which is a hypothesis for significant
difference in a single state. Hypothesis 3 was inferred for only 5 genes by
our analysis.
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Hypothesis 10 was chosen as the representative of the popular nonnull hy-
potheses in our analysis, whereas hypothesis 3 was chosen as the representa-
tive of hypotheses with very small (but nonzero) numbers of inferred genes.
For each of these two hypotheses, we examined the distribution of “esti-
mated effect sizes” for the set of genes inferred to have that hypothesis. The
key question is: how small of an effect size can be detected by our analysis?
We can get an upper bound on the effect size needed for hypothesis 10
by looking at the minimum estimated effect size among the genes g inferred
into the hypothesis 10 group. For each gene g inferred to have hypothesis
10, the estimated effect size is
Yg =
X
24
g −X
13
g
sg
,
where X
24
g is the mean of the expression levels Xgij over all individuals j
within states 2 and 4, whereas X
13
g is the mean of the expression levels
Xgij over all individuals j within states 1 and 3. The effect sizes are scaled
by sg, the pooled standard deviation of the expression levels for gene g
over the two groups (states 2 and 4 vs. states 1 and 3) and all individuals
[Flury and Riedwyl (1986)]. The minimum estimated effect size Yg found
for genes inferred to have hypothesis 10 was 0.11, which means that our
analysis can detect circadian effect sizes X
24
g −X
13
g that are as small as only
0.11 of the standard deviation sg. Part of the reason for this high sensitivity
is the somewhat large marginal probability φ10 = 0.12 that is estimated by
our analysis for hypothesis 10.
We also get an upper bound on the effect size needed for the less popular
hypothesis 3 by looking at the estimated effect size
Yg =
X
124
g −X
3
g
sg
for genes g inferred to have hypothesis 3. X
124
g is the mean of the expression
levels Xgij over all individuals j within states 1, 2 and 4, whereas X
3
g is
the mean of the expression levels Xgij over all individuals j within just
state 3, and again the effect sizes are scaled by sg, the pooled standard
deviation of the expression levels for gene g over the two groups (states 1,
2 and 4 vs. state 3) and all individuals. Among the five genes inferred to
have hypothesis 3, the minimum estimated effect size Yg was 0.32, which
suggests that our analysis requires larger effect sizes (0.32 of the standard
deviation sg) to detect a significant noncircadian effect. Again, part of the
reason for this reduced sensitivity is the much smaller marginal probability
φ3 = 0.001 of hypothesis 3 that is estimated from our model fit. However,
despite this reduced sensitivity, we still observe genes inferred into these
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nonnull and noncircadian categories within our analysis, which suggests that
the effect sizes needed for detection of nonnull effects are not unrealistic for
the current study. Indeed, we observe even larger minimum estimated effect
sizes among other nonnull hypotheses that still contained inferred genes. The
most extreme case is hypothesis 6, which has three inferred genes despite
having a large minimum estimated effect size (0.67 of the standard deviation
sg) and a small marginal probability φ6 = 0.001.
5. Summary and discussion. Motivated by a large study of sleep apnea
treatment, we have presented methodology for a relatively under-explored
hypothesis testing context: testing not only many units but also many hy-
potheses within each unit. This situation is prevalent in many biological in-
vestigations, where the units are usually genes and where the experimental
design dictates that expression data for an entire genome is to be measured
across several states. Our proposed Bayesian hierarchical model is a natural
framework for testing for differences across states while controlling for that
large number of comparisons that need to be made within the experimen-
tal design. In addition to comparison with previous methods, we have also
provided an extensive exploration and validation of our modeling assump-
tions. As shown in Section 3.3, our procedure also easily accommodates the
collapsing of certain hypotheses into larger groupings that may also be of
interest. Genes inferred into the treatment categories of hypotheses are can-
didates for future studies into more refined treatments of sleep apnea, as
well as general studies into the genetic basis of sleep behavior.
Many analyses of expression data across several conditions or states fo-
cus on the grouping of genes into clusters of similar expression patterns
[e.g., Medvedovic and Sivaganesan (2002), Ma et al. (2006)]. The focus of
our procedure differs substantially from a clustering-based analysis, since
our interest lies in using the experimental design to identify genes that fulfill
specific hypotheses. Interpretation of the results from a clustering analysis
is more difficult since one must assign biological hypotheses to each gene
cluster post hoc. However, although our model and implementation can be
easily generalized to an increasing number of conditions, the interpretation
of our own rapidly increasing space of possible hypotheses becomes more
difficult. Thus, as the number of states grows to be quite large, clustering-
based approaches become a more attractive alternative. Our methodology is
most appropriate for the frequent intermediary situation where one wants to
simultaneously test many genes × many hypotheses within each gene across
a modest number of states.
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SUPPLEMENTARY MATERIAL
Gibbs sampling implementation and full list of hypotheses
(DOI: 10.1214/09-AOAS241SUPP; .pdf). We provide details of our Markov
chain Monte Carlo implementation, which is based on a Gibbs sampling al-
gorithm [Geman and Geman (1984)]. We also give a full enumeration of the
hypotheses considered in Section 2.1.
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